The phase 2 trial that Roche ran with met mab had some really strange data. It had a very small N and it is hard to believe that they conducted a large phase 3 trial based on the data from phase 2
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.